新生儿复苏试验中替代知情同意流程:SAIL试验二次分析
SAIL随机试验的二次分析比较了产前知情同意与延迟知情同意(继续同意)两种模式下中心的招募率和结局。
要点
- 延迟同意中心招募合格婴儿比例显著高于仅产前同意中心(73% vs 41%)。
- 延迟同意中心招募的婴儿产前糖皮质激素暴露更少、男性更多、出生体重更高。
核心结论
- 提供延迟知情同意的中心招募了更高比例的合格高危婴儿,样本合并症更多,更具人群代表性。
研究设计与样本
- SAIL试验的二次分析,为开放标签、国际、多中心随机试验,纳入18个中心、9个国家、胎龄23至小于27周的婴儿。
- 比较仅产前知情同意中心与提供延迟知情同意(可含或不含产前同意)中心的招募率和结局。
临床怎么用
- 在新生儿复苏试验中,采用延迟知情同意流程可能提高高危婴儿的招募率并改善样本代表性。
局限性
- 本研究为二次分析,延迟同意路径随机分配的225名婴儿中34名(15%)未获得延迟同意而被排除分析。
- 有生活经验者未参与SAIL试验的设计或实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delivery room trials face ethical and logistical enrolment challenges, including requirements for prospective, antenatal, parental consent. The Sustained Aeration of Infant Lungs (SAIL) study was a randomised controlled trial of two resuscitation strategies at birth, enrolling infants using both prospective antenatal consent and deferred postnatal (consent-to-continue) pathways. We aimed to compare recruitment and outcomes between SAIL trial centres with deferred consent available versus centres only using prospective antenatal consent. METHOD: This study is a secondary analysis of the data from the open-label, international, multicentre, randomised SAIL trial. Infants born at 23 to less than 27 weeks' gestation at 18 centres across nine countries who were deemed to require intermittent positive pressure ventilation due to inadequate respiratory efforts or bradycardia, had no known major congenital anomalies, and were neither stillborn nor considered to be non-viable by their clinician were eligible for inclusion. Centres were compared by consent mode availability: antenatal consent only versus centres with deferred consent available. The primary outcome was the combined rate of death or bronchopulmonary dysplasia compared between consent type groups. People with lived experience did not contribute to the design or implementation of the SAIL trial. The SAIL trial was registered with ClinicalTrials.gov (NCT02139800). FINDINGS: The SAIL trial recruited 426 infants (222 [52%] were male and 204 [48%] were female) born from 371 mothers (218 [59%] were White) between Aug 27, 2014, and Sept 14, 2017. In 12 centres using only antenatal consent, 197 (41%) of 479 eligible infants were recruited and included in analysis compared with 229 (73%) of 313 eligible infants from six centres where deferred consent was available (with or without antenatal consent; absolute difference 31·78% [95% CI 24·46-39·10; p<0·0001]). Deferred consent was not obtained from 34 (15%) of 225 infants randomly assigned via the deferred pathway, who were excluded from this analysis. Compared with centres using only antenatal consent, infants recruited at deferred consent centres had less exposure to antenatal corticosteroids (166 [84%] of 197 vs 167 [73%] of 229 infants, p=0·012); were more likely to be male (88 [45%] vs 134 [59%], p=0·0065); were heavier (median birthweight 687 g [IQR 558-817] vs 767 g [661-870], p<0·0001); were less likely to be growth restricted (34 [27%] vs 19 [8%], p=0·0075); and less frequently intubated at birth (125 [63%] vs 105 [46%], p=0·0005). The rate of death or bronchopulmonary dysplasia at deferred consent centres was 65% (149/229) versus 57% (113/197) at antenatal consent centres (adjusted relative risk 1·18 [95% CI 0·98-1·42]). INTERPRETATION: Centres where deferred consent was available recruited a higher proportion of eligible infants at high risk who had more morbidities, reflecting a broader, more generalisable sample of the population compared with centres that only recruited using antenatal consent. FUNDING: Eunice Kennedy Shriver National Institute of Child Health and Human Development.
引用
- Owen LS, Foglia EE, Ratcliffe SJ, et al. Alternative consent processes in a neonatal resuscitation trial (SAIL): secondary analysis of an open-label, international, multicentre, randomised trial. Lancet Child Adolesc Health. 2025. PMID: 40816312. doi:10.1016/S2352-4642(25)00185-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。